Clinical Trial Update: Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SNS-595 in platinum-resistant epithelial ovarian cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• SNS-595

Snippet

Sponsor: Sunesis Pharmaceuticals | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-28